Sarcoma / 2009 / Article / Tab 1

Clinical Study

Primary Adult Renal Ewing's Sarcoma: A Rare Entity

Table 1

Treatment and outcome in the seven patients with primary renal Ewing’s sarcoma.
(a) Patients without metastatic disease at presentation

Age in yearsYear of diagnosisSexSide of renal primaryRadical nephrectomychemotherapySite of relapseDisease-free interval in monthsStatus at last follow upSurvival in months

501993MaleLeftYes4 VID/2 IENo relapse149.7Alive (no disease)149.7
342000MaleRightYes3 CVD/3 EPLung55.4Alive (stable disease)107.4
572007FemaleLeftYes1 VACLiver, spleen5.3Died (progressive disease)6.5
432007MaleLeftYes4MVAC > 2VIDE > 3VADBone5.1Alive (stable disease)15.6

(b) Patients with metastatic disease at presentation

Age in yearsYear of diagnosis SexSide of renal primary Radical nephrectomyMetastatic site at presentationchemotherapyTime to disease progression in monthsStatus at last follow upSurvival in months

351997FemaleLeftNoLiver, node3 PD/3ID 24Died (progressive disease)62.8
321999FemaleRightNoLiver, nodeEtoposide 0Died (progressive disease)26.5
502007MaleLeftNoLiver, adrenal4VIDE > 6VAC 12Died (progressive disease)13.1

Abbreviations: V: vincristine (vinblastine in MVAC), P: cisplatin, I: ifosfamide, D: doxorubicin, E: etoposide, A: actinomycin D (doxorubicin in IVAD).

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.